HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nifekalant hydrochloride, a novel class III antiarrhythmic agent, suppressed postoperative recurrent ventricular tachycardia in a patient undergoing coronary artery bypass grafting and the Dor approach.

Abstract
A patient with 3-vessel coronary artery disease and left ventricular aneurysm underwent coronary artery bypass grafting combined with the Dor approach. Five days later, ventricular tachycardia following short-coupled ventricular premature contractions suddenly occurred and was not responsive to class IB drugs (lidocaine and mexiletine), requiring frequent electrical cardioversion. After the administration of a novel class III drug, nifekalant hydrochloride, this electrical storm of ventricular tachycardia was completely suppressed together with the disappearance of ventricular premature contractions. Nifekalant hydrochloride (MS-551), a pure K(+) channel blocker, might be effective for postoperative recurrent ventricular tachyarrhythmias that are refractory to other antiarrhythmic agents.
AuthorsMakoto Sahara, Kouichi Sagara, Takeshi Yamashita, Hiroyuki Iinuma, Long-Tai Fu, Hiroshi Watanabe
JournalCirculation journal : official journal of the Japanese Circulation Society (Circ J) Vol. 67 Issue 8 Pg. 712-4 (Aug 2003) ISSN: 1346-9843 [Print] Japan
PMID12890916 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Anti-Arrhythmia Agents
  • Potassium Channel Blockers
  • Pyrimidinones
  • Mexiletine
  • nifekalant
  • Lidocaine
Topics
  • Aged
  • Anti-Arrhythmia Agents (classification, therapeutic use)
  • Coronary Artery Bypass (adverse effects)
  • Drug Resistance
  • Electric Countershock
  • Electrocardiography
  • Humans
  • Lidocaine (therapeutic use)
  • Male
  • Mexiletine (therapeutic use)
  • Potassium Channel Blockers (therapeutic use)
  • Pyrimidinones (therapeutic use)
  • Tachycardia, Ventricular (diagnosis, drug therapy, etiology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: